Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-two cases of primary hepatic tumors consisting of 11 hepatocellular carcinomas, 6 cholangiocarcinomas, 3 mixed hepatocellular and cholangiocellular carcinomas, and 2 biliary cystadenocarcinomas together with 8 cases of metastatic adenocarcinoma from various sites were studied by immunoperoxidase technic to demonstrate tissue polypeptide antigen. All of the tumors presumably derived from the epithelial lining of the bile duct, including cholangiocarcinoma, cholangiocarcinomatous portion of the mixed hepatocellular and cholangiocellular carcinoma, and biliary cystadenocarcinoma showed strong positive reaction. The hepatocellular carcinoma and the metastatic adenocarcinoma exhibited negative to weakly positive reactions. These results indicate that TPA can be of use in differentiating bile duct carcinomas from hepatocellular carcinoma and, to a lesser extent, from hepatic metastases of various adenocarcinomas.
 ...
PMID:Tissue polypeptide antigen--a marker antigen differentiating cholangiolar tumors from other hepatic tumors. 302 21

TNM stage, immunostaining with various monoclonal and polyclonal antibodies, analysis of distance of neighboring cells, remission rates, and survival were analyzed in 60 patients suffering from small cell anaplastic carcinoma of the lung. The majority of patients showed advanced tumors at the time of admission to hospital (T2, T3 stage). Distant metastases prior to chemotherapy were detected in 34 patients. Partial remissions lasting 2-4 months were observed in 38 patients, and complete remission was documented in 7 patients. The remission rate was independent of cell type but dependent on the stage of the tumor. Some 30 patients showed positive staining with an antibody recognizing epitopes detectable on carcinoembryonic antigen, whereas 60% of the tumors were positive to a polyclonal neuron-specific enolase antibody. Tissue polypeptide antigen was found to stain positively in 5 cases only. Some 14 patients with negative staining against the monoclonal antibody BMA 406/14 showed prolonged survival compared to patients with positive staining (P less than 0.05). Patients suffering from tumors with smaller distances between neighboring cells had worse prognoses compared to patients with larger distances (P less than 0.01). Survival of patients was found to be indistinguishable if cohorts were grouped according to T stage, N stage, or existence of distant metastases. Ten patients who underwent surgical treatment of tumors did not show prolonged survival compared to 50 patients treated by combined chemotherapy only.
 ...
PMID:TNM stage, immunohistology, syntactic structure analysis and survival in patients with small cell anaplastic carcinoma of the lung. 304 Jul 67

The emerging concept of autocrine/paracrine control of tumour cell proliferation coupled with the identification of several polypeptide mitogens has created new opportunities for the discovery of novel classes of antineoplastic drugs. Growth factors (for example, transforming growth factor alpha, fibroblast growth factor and platelet-derived growth factor) and, in certain cases, their receptors have been identified in a number of human tumours and their expression may contribute to unregulated cell proliferation. Selective antagonists that block the activity of these mediators may have important therapeutic utility in the management of cancer patients, particularly in metastatic disease where patterns of tumour cell dissemination may be strongly influenced by paracrine mediators. However, since many, if not all, of these growth factors are polypeptides with molecular weights over 5 kDa, the discovery of potent antagonists represents an important pharmacological challenge. Advances in understanding protein structure-function relationships will be essential in guiding rational attempts at generating growth factor antagonists through site-directed mutagenesis and peptide synthesis, while better insights into the mechanisms by which growth factors are synthesized, processed, released and exert their mitogenic effects may also reveal new sites for pharmacological assault. The availability of (low molecular weight) potent growth factor antagonists will allow the autocrine/paracrine hypothesis to be clinically tested and in the process will throw considerable light on the function of these growth regulatory molecules in vivo.
 ...
PMID:Growth factors as novel therapeutic targets in neoplastic disease. 307 70

Preoperative serum concentrations of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and a monoclonal-antibody-defined carcinoma-associated carbohydrate antigen, CA-50, were measured in 272 consecutive patients with histopathologically proven rectal carcinoma. The levels of all three tumour markers correlated directly to the stage of the disease. The serum TPA reflected both the local tumour burden and any metastatic spread, as shown by analysing mean levels of S-TPA and by the use of a Walker and Duncan regression model. S-CA-50 separated patients with and without distant metastases, but not with regard to the local tumour burden. Although the level of S-CEA correlated to the tumour stage, it did not discriminate patients with respect to locally advanced growth or generalized disease. In a multivariate analysis, the serum level of TPA was found to be the most informative preoperatively. Both S-CA-50 and S-CEA gave information additional to that provided by S-TPA in the prediction of the tumour stage (Dukes' stage A-D), and S-CA-50 was also useful in the prediction of metastatic disease.
 ...
PMID:Preoperative serum markers in carcinoma of the rectum and rectosigmoid. I. Prediction of tumour stage. 316 69

The antibody response of patients was used to characterize the autoantigens in human colorectal carcinoma. Twenty-seven primary and 13 metastatic carcinomas with paired normal tissues were extracted and transferred onto nitrocellulose membranes by the Western transfer technique. After the transfers were incubated with the serum of the patient from whom the tumor was derived, autoantigens were identified by indirect immunoperoxidase staining. All tumors contained at least one autoantigen. Six tumor-associated autoantigens, ranging in molecular weight from 26 to 58 kilodaltons (kD), were identified by antibodies in 25% or more of the sera. Eleven metastases expressed a 41-kD autoantigen that was present in only a third of the extracts of normal liver or lung. Thus, the number of dominant polypeptide autoantigens in colorectal carcinoma is restricted to six molecules. These autoantigens may be organ-associated antigens that are expressed by neoplastic cells. The 41-kD autoantigen may be a potential marker for metastases. A generic vaccine appears to be feasible for colorectal carcinoma since the number of dominant antigens is limited.
 ...
PMID:Expression of autoantigens in human colorectal carcinomas. Implications for a generic vaccine. 331 58

The levels of tissue polypeptide antigen (TPA) and beta 2 microglobulin (beta 2-MG) were measured in the serum of 38 patients with nasopharyngeal carcinoma (NPC). Using sera from 35 normal volunteers and blood donors, a normal range for these two tumour markers was established. The normal range for TPA was 40-148 IU/L (mean = 93), while that for beta 2-microglobulin was 0.9-2.0 mg/L (mean = 1.3). In the patients with NPC but without known metastases the range was 63-178 IU/L for TPA (mean = 111) and for beta 2-MG, the range was 1.0-3.1 mg/L (mean = 1.7). For those NPC patients with metastases to bone or liver, the mean TPA was 464 IU/L and the mean beta 2-MG was 4.3 mg/L. It appears that TPA and beta 2-MG are useful markers for the monitoring of NPC patients for metastatic disease, particularly TPA.
 ...
PMID:Tissue polypeptide antigen (TPA) and beta 2-microglobulin (beta 2-MG) as tumour markers in nasopharyngeal cancer. 355 79

The purpose of this study was to evaluate the clinical significance of different serum tumor markers in patients with breast cancer who developed recurrent disease. Determined were tissue polypeptide antigen (TPA), carcinoembryonic antigens (CEA), and phosphohexose isomerase (PHI). Serum samples of 411 breast cancer patients with either locoregional or metastatic recurrence were analyzed. Positive rates of all three markers depended on the clinical stage of the disease, with highest rates of elevated titers in advanced disease. In comparison, CEA and TPA are more sensitive markers than PHI. According to the site of recurrence, CEA exhibited the highest rate of elevated titers in patients with bone metastases and PHI in patients with visceral metastases. Using PHI in combination with CEA, sensitivity (ie, at least one marker is elevated) was increased by 6-20% compared to the results obtained with single marker analysis. However, for easier interpretation of the tumor marker results in clinical practice, it may be helpful to employ a product value of CEA and PHI.
 ...
PMID:Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients. 356 16

Tissue polypeptide antigen (TPA) is an oncofetal antigen found in human malignant tumors of various origins. We used radioimmunoassay to determine TPA levels in a total of 150 serum samples from 88 patients with different types of genitourinary cancers. The serum TPA level among cancer patients of all stages combined was higher than in normal healthy controls (p less than 0.05). However, when the patients with metastases were excluded from the analysis, the TPA titer was not significantly different from those of the normal controls. The difference in serum TPA between patients with local disease and patients with metastatic lesions was highly significant (p less than 0.0001). The serum TPA levels were significantly decreased in patients who responded to treatment; the levels were significantly increased in those who progressively became worse.
 ...
PMID:Tissue polypeptide antigen (TPA) as a predictor for genitourinary cancers and their metastases. 361 91

The cytoskeleton of colon (11 cases) and breast adenocarcinomas (9 cases) was characterized with the use of immunohistochemistry on tissue sections and one- and two-dimensional (2-D) gel electrophoresis of cytoskeletal extracts of tumor cells. By immunofluorescence, antibodies to epidermal cytokeratin (CK) and Mallory body CK recognized cytoplasmic filaments +/- desmosomal contacts, respectively, in both colon and breast adenocarcinomas. In addition, cytoskeletal extracts of both tumors showed similar CK polypeptides by 2-D gel electrophoresis. By immunoperoxidase, anti-actin antibody stained the apical margin of tumor cells in eight (73%) colon adenocarcinomas and four of five metastases, while diffuse cytoplasmic staining was seen in only one (9%) breast adenocarcinoma and not in five metastases. With 2-D gel electrophoresis, a cytoskeletal-associated doublet polypeptide was found in seven (64%) colon adenocarcinomas but not in the breast adenocarcinomas. By immunoblotting, the doublet did not consist of CK polypeptides, vimentin, or type IV collagen. These findings may facilitate the differentiation of colon and breast adenocarcinomas.
 ...
PMID:The use of cytoskeletal characteristics of tumor cells for the diagnosis of colon and breast adenocarcinomas. 378 57

In breast cancer, under rigorous and normalized conditions, the blood levels of carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) allow us: to differentiate with enough precision, in treated patients, the presence of tumour (EP) from illness-free situation (NED); to alert about the appearance of metastases and/or local relapse in patients put under systematic postoperative evolutional control; to evaluate the systemic palliative treatment response in patients with metastatic breast cancer and to formulate, in this case, prognostic predictions. Blood levels of CEA and TPA are, otherwise, unsuitable: to detect with accuracy the primary tumour presence; to warn about the risk of subclinical tumour existence (in treated patients in NED situation); to predict, in this last case, the chemotherapeutic treatment response, and to prevent about local relapses development. The independent but combined use of both antigens, appreciably raises the diagnostic success percentage with regard to that obtained when only one tumour marker was used.
 ...
PMID:[CEA and TPA in cancer of the breast. Findings and criteria of use]. 384 60


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>